Eton Pharmaceuticals appoints Judith Matthews as CFO effective June 1, 2026

Eton Pharmaceuticals, Inc.

Judith Matthews will become CFO on June 1, 2026, succeeding James Gruber who remains through May 31 then six-month consulting.
Annual base salary of $440,000, target bonus 45% of salary, one-time option for 37,000 shares vesting over 4 years.
Matthews was previously CFO of Iterum Therapeutics (2015-2026) and VP Finance at Durata Therapeutics.
Gruber to provide transition support via six-month consulting agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.